GlassScriptPhysician profile
Cuong-Dung Trong DO
NPI 1477574200
$22,824.84
in general payments reported to CMS, 2019-2025
32 companies · $2,999 in 2025
The $2,999 reported for 2025 was more than what 91% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,275 · 2020: $2,132 · 2021: $3,655 · 2022: $2,924 · 2023: $3,619 · 2024: $3,222 · 2025: $2,999.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,840.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,839.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eyevance Pharmaceuticals LLC | $2,758.75 | 2019-2023 | Tobradex St |
| Allergan, INC. | $2,587.71 | 2019-2022 | |
| Aerie Pharmaceuticals, INC. | $2,149.75 | 2019-2021 | |
| Alcon Vision LLC | $2,071.80 | 2019-2025 | Rocklatan, Hydrus Microstent, Tryptyr |
| Bausch & Lomb Americas INC. | $2,043.09 | 2022-2025 | Vyzulta, Miebo, Xiidra |
| Sun Pharmaceutical Industries INC. | $2,016.05 | 2019-2025 | Cequa |
| Abbvie INC. | $1,460.35 | 2022-2025 | Lumigan, Xen Glaucoma Treatment System, Vuity |
| Oyster Point Pharma, INC. | $1,446.40 | 2022-2025 | Tyrvaya, Ryzumvi |
| Mallinckrodt Hospital Products INC. | $1,036.24 | 2020-2025 | Acthar |
| Novartis Pharmaceuticals Corporation | $1,028.19 | 2019-2023 | |
| Amgen INC. | $600.72 | 2024-2025 | Tepezza |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $569.25 | 2019-2021 | |
| Johnson & Johnson Surgical Vision, INC. | $544.29 | 2019-2024 | Tecnis Iol, Tecnis Simplicity |
| Kala Pharmaceuticals, INC. | $403.07 | 2021-2022 | |
| Horizon Therapeutics Plc | $340.21 | 2022-2023 | Tepezza |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ani Pharmaceuticals, INC. | $310.16 | 2023-2025 | Purified Cortrophin Gel, Yutiq |
| Dompe US, INC. | $199.38 | 2021-2025 | Oxervate |
| Shire North American Group INC | $187.53 | 2019 | |
| Tarsus Pharmaceuticals, INC. | $180.66 | 2024-2025 | Xdemvy |
| Sight Sciences, INC. | $158.00 | 2020-2021 | |
| Ivantis, INC | $152.26 | 2019-2020 | |
| Rxsight INC | $136.38 | 2022-2023 | Rxsight Contact Lens, Rxsight Light Adjustable Lens (Rxlal), Rxsight Injector Cartridge |
| Ocular Therapeutix, INC. | $88.94 | 2022-2023 | Dextenza |
| Biogen, INC. | $85.46 | 2022 | |
| Apellis Pharmaceuticals, INC. | $65.15 | 2023-2024 | Syfovre |
| Thea Pharma INC. | $65.14 | 2023-2025 | Iyuzeh |
| Glaukos Corporation | $38.08 | 2021-2023 | Istent Inject Trabecular Micro-Bypass System Model G2-M-Is |
| Akorn Operating Company LLC | $21.62 | 2021 | |
| Akorn, INC. | $20.49 | 2020 | |
| Rayner Intraocular Lenses Limited | $20.41 | 2025 | Omidria |
| Santen INC. | $19.91 | 2023 | Verkazia |
| Carl Zeiss Meditec Ag | $19.40 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cuong-Dung DO listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.